A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
A phase 2 trial of Sonesitatug vedotin, Rilvegostomig, Trastuzumab, Trastuzumab deruxtecan, Capecitabine and Fluorouracil (5-FU) in oesophageal cancer, run by AstraZeneca, now recruiting.
Overview
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma is a phase 2 interventional study registered as NCT07069712 by AstraZeneca, with 100 participants planned, started 2025-07-17 and due to reach its primary completion in 2027-11-03. Interventions recorded: Sonesitatug Vedotin, Rilvegostomig, Trastuzumab Deruxtecan (T-DXd), Capecitabine, 5-Fluorouracil (5-FU) and FLOT Chemotherapy.
Similar pages
not linked directly; found by shared links- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Rilvegostomig, Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag pipeline.
- TrialSonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Shares Sonesitatug vedotin, Rilvegostomig, Capecitabine, Oesophageal cancer and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Fluorouracil (5-FU), Capecitabine, Trastuzumab, Trastuzumab deruxtecan and the tag pipeline.
- TrialRoll Over StudY for Patients Who Have Completed a Previous Oncology Study With Osimertinib (TAGRISSO) (ROSY-T)
Shares Parexel, AstraZeneca and the tag pipeline.
- TrialBCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Shares Parexel, AstraZeneca and the tag pipeline.
- TrialNovel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
- TrialRilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Shares Rilvegostomig, Capecitabine, AstraZeneca and the tag pipeline.
- TrialPhase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
Shares Rilvegostomig, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.